A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings

Applied Immunohistochemistry and Molecular Morphology

Volumn 17, Issue 1, 2009, Pages 57-67

  Knudsen, Beatrice S ^a   Zhao, Ping ^b   Resau, James ^b   Cottingham, Sandra ^b   Gherardi, Ermanno ^d   Xu, Eric ^b   Berghuis, Bree ^b   Daugherty, Jennifer ^b   Grabinski, Tessa ^b   Toro, Jose ^b   Giambernardi, Troy ^b   Skinner, R Scot ^c   Gross, Milton ^c   Hudson, Eric ^b   Kort, Eric ^b   Lengyel, Ernst ^e   Ventura, Aviva ^a   West, Richard A ^b   Xie, Qian ^b   Hay, Rick ^b   Woude, George Vande ^b   Cao, Brian ^b   more..

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b SPECTRUM HEALTH   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^d MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

c MET; Glioma; Immunohistochemistry; Molecular diagnostics; Monoclonal antibody; Ovarian cancer

Indexed keywords

FORMALDEHYDE; MET4 ANTIBODY; MONOCLONAL ANTIBODY; PARAFFIN; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ARTICLE; B LYMPHOCYTE; BASAL CELL; CANCER CELL; CELL NUCLEUS; CELL SURFACE; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENDOTHELIUM CELL; EPITHELIUM CELL; GLIOMA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; MALE; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STAINING; STROMA CELL; T LYMPHOCYTE; TUMOR XENOGRAFT; CHEMISTRY; FEMALE; NEOPLASM; OVARY TUMOR; PATHOLOGY; STANDARD; TISSUE FIXATION; VALIDATION STUDY;

ANTIBODIES, MONOCLONAL; FEMALE; FORMALDEHYDE; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASMS; OVARIAN NEOPLASMS; PARAFFIN EMBEDDING; PROTO-ONCOGENE PROTEINS C-MET; TISSUE FIXATION; TUMOR MARKERS, BIOLOGICAL;

EID: 58749106485     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181816ae2     Document Type: Article

References (38)

1. Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4:915-925.
2. Rosario M, Birchmeier W. How to make tubes: signaling by the Met receptor tyrosine kinase. Trends Cell Biol. 2003;13:328-335. (Pubitemid 36638800)
3. Jeffers M, Fiscella M, Webb CP, et al. The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci USA. 1998;95:14417-14422. (Pubitemid 28549382)
4. Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003;63:6272-6281. (Pubitemid 37255174)
5. Peschard P, Fournier TM, Lamorte L, et al. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell. 2001;8:995-1004. (Pubitemid 34031802)
6. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET protooncogene in papillary renal carcinomas. Nat Genet. 1997;16:68-73. (Pubitemid 27198158)
7. Di Renzo MF, Olivero M, Giacomini A, et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res. 1995;1:147-154.
8. Kuniyasu H, Yasui W, Kitadai Y, et al. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun. 1992;189:227-232. (Pubitemid 23030031)
9. Naldini L, Weidner KM, Vigna E, et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. Embo J. 1991;10:2867-2878. (Pubitemid 21905304)
10. Rosen EM, Knesel J, Goldberg ID. Scatter factor and its relationship to hepatocyte growth factor and met. Cell Growth Differ. 1991; 2:603-607.
11. Di Renzo MF, Olivero M, Martone T, et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene. 2000;19:1547-1555. (Pubitemid 30175676)
12. Lee JH, Han SU, Cho H, et al. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene. 2000;19: 4947-4953. (Pubitemid 30808359)
13. Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 2005;65:1479-1488. (Pubitemid 40270177)
14. Puri N, Ahmed S, Janamanchi V, et al. c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res. 2007;13:2246-2253. (Pubitemid 46649894)
15. Zhuang Z, Park WS, Pack S, et al. Trisomy 7-harbouring nonrandom duplication of the mutant Met allele in hereditary papillary renal carcinomas. Nat Genet. 1998;20:66-69. (Pubitemid 28410347)
16. Martens T, Schmidt NO, Eckerich C, et al. A novel one-armed antic- Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res. 2006;12:6144-6152. (Pubitemid 44703780)
17. Puri N, Khramtsov A, Ahmed S, et al. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 2007; 67:3529-3534. (Pubitemid 46762132)
18. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007;67:4408-4417. (Pubitemid 46815090)
19. Pozner-Moulis S, Cregger M, Camp RL, et al. Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model. Lab Invest. 2007;87:251-260. (Pubitemid 46353942)
20. Gherardi E, Coffer A. Purification and characterization of scatter factor. EXS. 1991;59:53-62.
21. Gherardi E, Youles ME, Miguel RN, et al. Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA. 2003;100:12039-12044. (Pubitemid 37271511)
22. Rong S, Oskarsson M, Faletto DL, et al. Tumorigenesis induced by co-expression of human hepatocyte growth factor and the human met protooncogene leads to high levels of expression of the ligand and receptor. Cell Growth & Diff. 1993;4:563-569.
23. Chen D, Adenekan B, Chen L, et al. Syndecan-1 expression in locally invasive and metastatic prostate cancer. Urology. 2004;63: 402-407. (Pubitemid 38234455)
24. Gmyrek GA, Walburg M, Webb CP, et al. Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. Am J Pathol. 2001;159:579-590. (Pubitemid 32751088)
25. Ridler TW, Calvard ES. Picture thresholding using an iterative selection method. Syst Mun Cybern. 1978;8:630-632.
26. Russ J. The Image Processing Handbook. 4th ed. Boca Raton, FL: CRC Press; 2002:732.
27. Altstock RT, Stein GY, Resau JH, et al. Algorithms for quantitation of protein expression variation in normal versus tumor tissue as a prognostic factor in cancer: Met oncogene expression, and breast cancer as a model. Cytometry. 2000;41:155-165.
28. Hay RV, Cao B, Skinner RS, et al. Radioimmunoscintigraphy of tumors autocrine for human met and hepatocyte growth factor/ scatter factor. Mol Imaging. 2002;1:56-62.
29. Hay RV, Cao B, Skinner RS, et al. Nuclear imaging of Metexpressing human and canine cancer xenografts with radiolabeled monoclonal antibodies (MetSeek). Clin Cancer Res. 2005;11: 7064S-7069S. (Pubitemid 41428705)
30. Humphrey PA, Zhu X, Zarnegar R, et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol. 1995; 147:386-396.
31. Knudsen BS, Edlund M. Prostate cancer and the met hepatocyte growth factor receptor. In: Vande Woude GF, Klein G, eds. Advances in Cancer Research. Vol 91. San Diego: Elsevier; 2004: 31-67.
32. van Leenders G, van Balken B, Aalders T, et al. Intermediate cells in normal and malignant prostate epithelium express c-MET: implications for prostate cancer invasion. Prostate. 2002;51:98-107.
33. Jiao Y, Zhao P, Zhu J, et al. Construction of human naive Fab library and characterization of anti-met Fab fragment generated from the library. Mol Biotech. 2005;31:41-54. (Pubitemid 41208421)
34. Gonzatti-Haces M, Seth A, Park M, et al. Characterization of the TPR-MET oncogene p65 and the MET protooncogene p140 protein-tyrosine kinases. Proc Natl Acad Sci USA. 1988;85:21-25.
35. Koochekpour S, Jeffers M, Rulong S, et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res. 1997;57:5391-5398. (Pubitemid 27516379)
36. Moon YW, Weil RJ, Pack SD, et al. Missense mutation of the MET gene detected in human glioma. Mod Pathol. 2000;13:973-977.
37. Fischer U, Muller HW, Sattler HP, et al. Amplification of the MET gene in glioma. Genes Chromosomes Cancer. 1995;12:63-65.
38. Sawada K, Radjabi AR, Shinomiya N, et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 2007; 67:1670-1679. (Pubitemid 46383393)